Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

913
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
913
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

680
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
680
Vaccinations01:51

Vaccinations

51.1K
Overview
51.1K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

2.4K
The pathophysiology of pneumonia involves the following steps:
2.4K
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

2.5K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
2.5K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

3.3K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteomic and biochemical characterization of Bothrops pubescens (Serpentes: Viperidae) venom.

Toxicon : official journal of the International Society on Toxinology·2025
Same author

Leaf Saponins of <i>Quillaja brasiliensis</i> as Powerful Vaccine Adjuvants.

Pharmaceutics·2025
Same author

Conjugation Mechanism for Pneumococcal Glycoconjugate Vaccines: Classic and Emerging Methods.

Bioengineering (Basel, Switzerland)·2022
Same author

ISCOM-Matrices Nanoformulation Using the Raw Aqueous Extract of <i>Quillaja lancifolia</i> (<i>Q. brasiliensis</i>).

BioNanoScience·2022
Same author

Reports of Doses Administered and Adverse Reactions to Snake Antivenom Used in Uruguay in 2018.

Frontiers in toxicology·2022
Same author

Polyvalent Bacterial Lysate Protects Against Pneumonia Independently of Neutrophils, IL-17A or Caspase-1 Activation.

Frontiers in immunology·2021

Related Experiment Video

Updated: Jan 5, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.1K

Next-Generation Whole-Cell Pneumococcal Vaccine.

Victor Morais1, Esther Texeira2, Norma Suarez3

  • 1Department of Biotechnology, Institute of Hygiene, Faculty of Medicine, University of the Republic, Montevideo 11600, Uruguay. vmorais@higiene.edu.uy.

Vaccines
|October 19, 2019
PubMed
Summary

New whole-cell pneumococcal vaccines (WCVs) show promise for broad protection against Streptococcus pneumoniae. These cost-effective vaccines are advancing through clinical trials, offering hope for global public health.

Keywords:
RM200Streptococcus pneumoniaevirulence factorswhole-cell vaccine

More Related Videos

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

46.5K
Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.3K

Related Experiment Videos

Last Updated: Jan 5, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.1K
Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

46.5K
Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.3K

Area of Science:

  • Bacteriology
  • Vaccinology
  • Public Health

Background:

  • Streptococcus pneumoniae poses a significant global health threat, causing invasive pneumococcal diseases.
  • Current Pneumococcal Conjugate Vaccines (PCVs) have reduced disease rates but lack universal serotype coverage and affordability.
  • There is a critical need for novel vaccines offering comprehensive protection and long-lasting immunity at a lower cost.

Purpose of the Study:

  • To evaluate the potential of Whole-Cell Pneumococcal Vaccines (WCVs) as a next-generation solution for pneumococcal disease.
  • To highlight the advantages of WCVs, including broad antigen expression and cost-effectiveness compared to recombinant vaccines.

Main Methods:

  • Development of novel WCVs utilizing an unencapsulated Streptococcus pneumoniae serotype.
  • Expression of multiple bacterial antigens within the whole-cell vaccine platform.
  • Clinical evaluation through ongoing Phase 1/2 human trials.

Main Results:

  • WCVs demonstrate the potential for broad serotype coverage and antigen expression.
  • The manufacturing process for WCVs is more cost-effective than traditional recombinant vaccines.
  • Early-stage human trials indicate WCVs are a promising candidate for pneumococcal disease prevention.

Conclusions:

  • Whole-Cell Pneumococcal Vaccines represent a promising advancement in combating Streptococcus pneumoniae infections.
  • These vaccines offer a potentially more accessible and effective strategy, particularly for developing nations.
  • Further research and clinical development are warranted to establish WCVs as a primary intervention.